New York Times: March 19, 2019. With an overwhelmingly large number of women reporting adverse effects to their breast implants, collectively known as breast implant illness, the FDA finally agrees to review the devices.
Read More »Author: Caroline Bradford
What Does Gottlieb’s Resignation Mean for Medtech?
Medtech: March 6, 2019. FDA Commissioner Scott Gottlieb sent in his resignation, but what does it mean for drug and device safety? NCHR President, Dr. Zuckerman, weighs in.
Read More »NCHR Statement to the Maryland State House Environmental Committee, Artificial Turf
March 1, 2019. NCHR’s Jack Mitchell made a statement at the Maryland State House Environmental Committee regarding artificial turf and its negative effects.
Read More »The Implant Files Sparked Reform Around The World. Here’s Why We’re Still Reporting.
ICIJ: February 27, 2019. The International Consortium of Investigative Journalists continue to scrutinize implants and their effect on people worldwide.
Read More »NCHR Testimony to FDA on Selinexor for Relapsed Refractory Multiple Myeloma
February 26, 2019. Selinexor has serious risks, and we don’t know if it works. Tell FDA to wait until the randomized trial is analyzed to make a decision.
Read More »